Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700

International Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 64-69

  Utz, Irene ^a   Spitaler, Martin ^a   Rybczynska, Maria ^a   Ludescher, Christof ^a   Hilbe, Wolfgang ^a   Regenass, Urs ^b   Grunicke, Hans ^a   Hofmann, Johann ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 42700; MIDOSTAURIN; PROTEIN KINASE C; RHODAMINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CANCER THERAPY; CELL PROLIFERATION; ENZYME ACTIVITY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SUPPRESSOR CELL; TISSUE CULTURE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION; GENES, MDR; HELA CELLS; HUMANS; RHODAMINES; STAUROSPORINE; TRANSFECTION;

EID: 0032479414     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980703)77:1<64::AID-IJC11>3.0.CO;2-9     Document Type: Article

References (20)

1. ANDREJAUSKAS-BUCHDUNGER, E. and REGENASS, U., Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res., 52, 5353-5358 (1992).
2. BENSON, A.B., III, TRUMP, D. L., KOELLER, J.M., EGORIN, M.I., OLMAN, E.A., WITTE, R.S., DAVIS, T. E. and FORMEY, D.C., Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat. Rep., 69, 795-799 (1985).
3. CHAUDHARY, P.M. and RONINSON, I.B., Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66, 85-94 (1991).
4. CZENDLIK, C. and GRAF, P., Safety, tolerability and pharmacokinetics of CGP 41251, a protein kinase C inhibitor (phase I study). Ann. Oncol., 7(Suppl. 1), 264 (1996).
5. DONG, Z., WARD, N.E., FAN, D., GUPTA, K.P. and O'BRIAN, C.A., In vitro model for intrinsic drug resistance: effects of protein kinase C activators on chemosensitivity of cultured human colon cancer cells. Mol. Pharmacol., 39, 563-569 (1991).
6. GEKELER, V., BOER, R., ÜBERALL, F., ISE, W., SCHUBERT, C., UTZ, I., HOFMANN, J., SANDERS, K.H., SCHACHTELE, C., KLEMM, K. and GRUNICKE, H., Effects of the selective bisindolylmaleimid protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Brit. J. Cancer, 74, 897-905 (1996).
7. GERMANN, U.A., CHAMBERS, T.C., AMBUDKAR, S.V., LICHT, T., CARDARELLI, C.O., PASTAN, I. and GOTTESMAN, M.M., Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J. biol. chem., 217, 1708-1716 (1996).
8. GOTTESMAN, M.M., How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 53, 747-754 (1993).
9. HOFMANN, J., UEBERALL, F., EGLE, A. and GRUNICKE, H., B-859-35, a new drug with anti-tumor activity, reverses multi-drug resistance. Int. J. Cancer, 47, 870-874 (1991).
10. HOFMANN, J., WOLF, A., SPITALER, M., BÖCK, G., LUDESCHER, C. and GRUNICKE, H., Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J. Cancer Res. clin. Oncol., 118, 361-366 (1992).
11. KANE, S.E., REINHARD, D.H., FORDIS, M.C., PASTAN, I. and GOTTESMAN, M.M., A new vector using the human multidrug resistance gene as a selectible marker enables overexpression of foreign genes into eukaryotic cells. Gene, 84, 439-446 (1989).
12. LOOR, F., BOESCH, D., GAVERIAUX, C., JACHEZ, B., POURTIER-MANZANEDO, A. and EMMER, G., SDZ-280-446, a novel semi-synthetic cyclopeptide: in vitro circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. Brit. J. Cancer, 65, 11-18 (1992).
13. LUM, B.L., GOSLAND, M.P., KAUBISCH, S. and SIKIC, B.I., Molecular targets in oncology: implications of the multidrug resistance gene. Pharmaco-therapy, 13, 88-109 (1993).
14. MA, L., MARQUARDT, D., TAKEMOTO, L. and CENTER, M.S., Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J. biol Chem., 266, 5593-5599 (1991).
15. MEYER, T., REGENASS, U., FABBRO, D., ALTERI, E., RÖSEL, J., MÜLLER, M., CARVATTI, G. and MATTER, A., A derivative of staurospprine (CGP 41251) shows selectivity for PKC inhibition and in vitro antiproliferative as well as in vivo antitumor activity. Int. J. Cancer, 43, 851-856 (1989).
16. NOONAN, K.E., BECK, C., HOLZMAYER, T.A., CHIN, J.E., WUNDER, J.S., ANRULIS, I.K., GAZDAR, A.F., WILLMAN, C.L., GRIFFITH, B., VON HOFF, D.D. and RONINSON, I.B., Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. nat. Acad. Sci. (Wash.), 87, 7160-7164 (1990).
17. O'BRIAN, C.A., FAN, D., WARD, N.E., SEID, C. and FIDLER, I.J., Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett., 246, 78-82 (1989).
18. SAMPSON, E., WOLFF, C.L. and ABRAHAM, I., Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett., 68, 7-14 (1993).
19. UTZ, I., HOFER, S., REGENASS, U., HILBE, W., THALER, J., GRUNICKE, H. and HOFMANN, J., The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 57, 104-110 (1994).
20. YANG, J.-M., CHIN, K.-V. and HAIT, W.N., Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res., 56, 3490-3494 (1996).